Lantern Pharma Inc. has generated a new class of highly specific and highly potent antibody-drug conjugates (ADCs) with a cryptophycin drug-payload, in collaboration with Bielefeld University.
Jiangsu Tasly Diyi Pharmaceutical Co. Ltd. has divulged Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of inflammation, infection, cancer and autoimmune disease.
Redx Pharma plc has closed its biggest transaction to date, selling a preclinical KRAS inhibitor program to Jazz Pharmaceuticals plc in a potential $880 million deal. Of that, $10 million will be paid up front, with the balance to come in development and commercialization milestones. For any product that makes it to market, Redx will in addition receive tiered mid-single digit percentage royalties.
Doma Biopharmaceutical (Suzhou) Co. Ltd. has disclosed antibody-drug conjugates comprising bispecific antibodies (E-6C4-M-2F11) targeting EGFR (HER1; erbB1) and hepatocyte growth factor receptors (HGFR; MET) covalently linked to cytotoxic drugs through a linker reported to be useful for the treatment of cancer.
Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.
Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Cellectar Biosciences Inc. has released promising preclinical data for its proprietary novel α-emitting phospholipid radiotherapeutic conjugate, CLR-121225 (225Ac-CLR-121225), an actinium-labeled phospholipid ether, in refractory pancreatic cancer mouse xenograft models.
